Replies to post #228495 on Biotech Values

[jbog]

I see Gilead is Claiming 60% of the U.S. Retail Market. That's up a little.

[DewDiligence]

GILD 1Q20 HCV sales=$729M, +16% QoQ, -8% YoY. The geographic breakdown was: US $398M; EU $148M; RoW $183M.

http://investors.gilead.com/news-releases/news-release-details/gilead-sciences-announces-first-quarter-2020-financial-results

GILD’s worldwide HCV patient starts in 1Q20 (CC slide #43) was flat vs 4Q19 at 45K (increasing from 28K to 29K in the US), implying an increase in average selling price per HCV patient.

--
CC slides:
http://investors.gilead.com/static-files/af4599eb-4fb8-4cf7-96a1-38caf477e9b4